Media Articles Related to Avalide (Irbesartan / Hydrochlorothiazide)
1st Gulf Hypertension Conference, 26-29 January 2015, Dubai
Source: Conferences News From Medical News Today [2014.11.13]
Research has highlighted that more than 37% of people in the UAE and 26% in KSA are suffering from hypertension, known as 'the silent killer' due to its rare display of symptoms.
Hypertension medication linked with reduced ALS risk
Source: Hypertension News From Medical News Today [2014.11.11]
A new study has found that the use of angiotensin-converting enzyme inhibitors is associated with a reduced risk of developing the neurological disorder ALS.
Could an explosive compound reduce hereditary hypertension risk for women?
Source: Hypertension News From Medical News Today [2014.11.11]
Researchers from Germany found that an explosive compound called PETN lowered the systolic blood pressure of female rats born to parents with hypertension.
Lack of transcription factor FoxO1 triggers pulmonary hypertension
Source: Hypertension News From Medical News Today [2014.10.30]
Pulmonary hypertension is characterised by uncontrolled division of cells in the blood vessel walls. As a result, the vessel walls become increasingly thick.
Research suggests team-based care is most effective way to control hypertension
Source: Hypertension News From Medical News Today [2014.10.24]
Patients diagnosed with high blood pressure are given better control of their condition from a physician-pharmacist collaborative intervention than physician management alone, according to new...
Published Studies Related to Avalide (Irbesartan / Hydrochlorothiazide)
A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review. [2011.07]
Hypertension is difficult to treat in patients with type 2 diabetes mellitus (T2DM) or obesity. Combination therapies are often required to effectively lower blood pressure (BP) and attain BP goals... In patients with moderate or severe hypertension and with a BMI >/= 30 kg/m(2), initial treatment with irbesartan/HCTZ combination therapy was more effective than irbesartan monotherapy.
Comparative bioavailability of two irbesartan/hydrochlorothiazide tablet formulations in Indonesian healthy subjects. 
AIM: The bioavailability of two 300 mg irbesartan (CAS 138402-11-6)/12.5 mg hydrochlorothiazide (CAS 58-93-5) tablet formulations was compared, using Co-Ir-vell tablets as test formulation and the originator product as reference formulation... CONCLUSION: These results indicated that the two formulations of irbesartan/hydrochlorothiazide were bioequivalent; therefore they may be prescribed interchangeably.
Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender. 
This analysis aimed to explore whether low-dose irbesartan/hydrochlorothiazide (HCTZ) has superior blood pressure (BP)-lowering efficacy over low-dose valsartan/HCTZ in the elderly and across both genders. This is a post-hoc analysis of data from a multicenter, parallel group, open-label, blinded-endpoint study in patients with hypertension uncontrolled with HCTZ monotherapy.
Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. [2009.10]
This prospective, double-blind, multicenter trial compared the safety and tolerability of irbesartan/hydrochlorothiazide (HCTZ) fixed-dose combination therapy with irbesartan monotherapy in patients with severe hypertension (seated diastolic blood pressure (SeDBP) >or=110 mm Hg, mean BP 172/113 mm Hg at baseline)...
* Raltegravir, the first in a new class of orally administered HIV type-1 (HIV-1) integrase inhibitors, selectively inhibits the strand transfer activity of HIV-1 and its integration into human DNA, a key stage in retroviral propagation, thereby limiting viral replication and the infection of new cells...
Clinical Trials Related to Avalide (Irbesartan / Hydrochlorothiazide)
Adalat ® XL® vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients [Recruiting]
The study consists of a 12 week run-in period when all subjects are stabilized on a single
dose of Avalide (300 mg/12. 5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends,
subjects will be randomly assigned to start the addition of either Adalat XL or Tiazac XC for
18 weeks of treatment. Subjects will have a 1 in 2 chance of receiving the study drug Adalat
XL and a 1 in 2 chance of receiving the drug Tiazac XC. An end of treatment visit will be
done 18 weeks after start of study drug. The expected duration of the study is 30 weeks. The
purpose of this study is to compare the change in proteinuria, through a urine test, while
taking study drug until high blood pressure (BP) is reduced to near normal levels in study
subjects with diabetic nephropathy and hypertension.
AMISH : Aprovel for Management of Isolated Systolic Hypertension [Completed]
To compare the antihypertensive efficacy and tolerability of irbesartan and
irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus
hydrochlorothiazide in the treatment of isolated systolic hypertension.
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients [Recruiting]
I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients [Completed]
- To evaluate control rate of Blood Pressure ≤ 140/90 mm Hg in non-diabetic patients, and
≤ 130/80 mm Hg in diabetic patients.
- To determine percentage of patients achieving blood pressure control according to their
profile (naïve, switch, patient history, etc…) at the end of the trial.
I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy [Recruiting]
- To evaluate Blood Pressure (BP) reduction to the targeted values (BP ≤ 140/90 mm Hg in
non-diabetic patients, and ≤ 130/80 mm Hg in diabetic patients).
- To emphasize and to evaluate the benefit of Irbesartan in the reduction of left
ventricular mass index in hypertensive patients with left ventricular hypertrophy.
- To demonstrate safety of Irbesartan in this population.
Reports of Suspected Avalide (Irbesartan / Hydrochlorothiazide) Side Effects
Drug Ineffective (45),
Blood Pressure Increased (40),
Medication Error (16),
Blood Pressure Inadequately Controlled (11),
Oedema Peripheral (11),
Back Pain (10),
Nausea (10), more >>